Gilead Sciences, Inc.

Gilead Sciences, Inc. and Tango Therapeutics, Inc., a company focused on the discovery and development of novel cancer therapies, have entered a global strategic collaboration to discover, develop, and commercialize a pipeline of innovative targeted immuno-oncology treatments for patients with cancer. Under the multi-year collaboration, Tango will perform target discovery and validation and Gilead will have…

China National Drug Administration (CNDA) has approved Gilead Sciences’ Genvoya (elvitegravir 150 mg/cobicistat 150 mg/emtricitabine 200 mg/tenofovir alafenamide 10 mg or E/C/F/TAF) for the treatment of HIV-1 infection. Genvoya is the first TAF-based single tablet regimen for the treatment of HIV to be approved in China. Genvoya is indicated in China as a complete regimen for…

The FDA has approved Gilead Sciences’s once-daily oral Truvada (emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)—in combination with safer sex practices—to reduce the risk of sexually acquired HIV-1 in at-risk adolescents. The safety and efficacy profile of Truvada for HIV prevention in uninfected adults, a strategy called pre-exposure prophylaxis (PrEP), is well established, and Truvada for…

Gilead Sciences Announces Fourth Quarter and Full Year 2017 Financial Results.  Total revenues for the fourth quarter of 2017 were $5.9 billion compared to $7.3 billion for the same period in 2016. Net loss for the fourth quarter of 2017 was $3.9 billion, or $2.96 loss per share, compared to net income of $3.1 billion,…

Gilead Sciences, Inc. and its cell therapy subsidiary Kite have entered into a definitive agreement to acquire Cell Design Labs, Inc., gaining new technology platforms that will enhance research and development efforts in cellular therapy. Under the terms of the agreement, Gilead will acquire all of the outstanding shares of Cell Design Labs, which includes the approximately 12.2…